Clinical Study to Assess Safety and Efficacy of a New Armsleeve in the Management of Arm Lymphoedema

Inclusion Criteria: * Unilateral secondary upper limb lymphoedema of stage II or III, following breast cancer * Patients hospitalized for an intensive phase of decongestive lymphoedema therapy (DLT) for whom a decrease of lymphoedema volume has been achieved during hospitalization * Lymphoedema with evident pitting sign (assessed as ++ or +++) * Requiring compression therapy for, at least, the next 3 months. * Affected arm that fits with one of the 6 standard sizes of the Auto-Adjustable MOBIDERM® armsleeve provided. * Signed informed consent prior to any study-mandated procedure. * Not under any administrative or legal supervision. * Covered by a health insurance system Exclusion Criteria: * Stage I lymphoedema * Active cellulitis * Lymphoedema associated with active cancer needing acute chemotherapy * Motor and sensitive neurological deficiency * Post-operative oedema (i.e acute oedema following breast cancer-related surgery) * Patient participating in any other clinical study * Unlikely to be followed up to 3 months with clinical assessment